However, the improvement of overall survival (OS) did not reach statistical significance ( 19 , 20 ), and the clinical use of related drugs in China is still not approved.
← all excerpts
Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review.
1
—
—